This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Investigations

Authoring team

General screening:

  • blood glucose, plasma calcium and potassium – hypercalcemia and hypokalemia can cause nephrogenic diabetes insipidus
  • serum sodium - may be raised
  • serum and urine osmolarity - plasma osmolality should be high and urine osmolality should be low. In cases of psychogenic polydipsia then generally the plasma osmolality is low
  • confirm existence of polyuria - more than 3.0 L urine in 24 hours

More specialist investigations:

  • fluid deprivation test with addition of exogenous vasopressin - usually, desmopressin
  • measurement of plasma ADH levels in response to hypertonic saline infusion in difficult cases
  • therapeutic trial of vasopressin - requires specialist supervision and indicated only if plasma ADH measurements are not available and the diagnosis is uncertain - 10 mcg per day given intranasally - cranial diabetes insipidus patients improve, nephrogenic diabetics are unchanged, primary polydipsia patients develop progressive hyponatraemia

References:

  1. Levy M, Prentice M, Wass J. Diabetes insipidus. BMJ. 2019 Feb 28;364:l321. doi: 10.1136/bmj.l321.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.